ADC Biotechnology (ADC Bio), a St. Asaph, North Wales-headquartered contract services company for antibody drug conjugates (ADCs), is investing $11 million for a bioconjugation facility at its new site in Deeside, North Wales, UK.

The 6,500-square-meter facility, scheduled to be operational by December 2018, will support manufacturing in all clinical phases and small-scale commercial production of ADCs. It will provide GMP production suites equipped with vessels of 10 liters up to a few hundred liters for batch sizes from 100 grams up to a kilogram. The new integrated facility will enable ADC Bio to complement its technical services business that provides small -scale R&D through to preclinical testing with three on-site laboratories and analytical testing capabilities.

The bioconjugation facility will provide capabilities ranging from R&D technical services, quality control, quality assurance, warehousing, and process development through to manufacturing. ADC Bio will have other free capacity to scale from early clinical phases into late-phase and commercial manufacturing within the same footprint at the new facility.

Subsequent phases are planned for 2018 and will add further capacity for large-scale clinical and commercial, and potentially, and dosage-form production (fill/finish).

Source: ADC Biotechnology